Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.96 SEK | +0.17% | -17.09% | -61.36% |
Apr. 15 | Oncopeptides AB Secures National Reimbursement for Pepaxti in Spain | CI |
Apr. 04 | Oncopeptides AB Provides Sales Guidance for the First Quarter of 2024 | CI |
Sales 2024 * | 105M 9.59M | Sales 2025 * | 196M 17.87M | Capitalization | 292M 26.69M |
---|---|---|---|---|---|
Net income 2024 * | -244M -22.28M | Net income 2025 * | -174M -15.89M | EV / Sales 2024 * | 0.81 x |
Net cash position 2024 * | 208M 18.96M | Net cash position 2025 * | 58.84M 5.37M | EV / Sales 2025 * | 1.19 x |
P/E ratio 2024 * |
-1.94
x | P/E ratio 2025 * |
-2.84
x | Employees | 57 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.37% |
Latest transcript on Oncopeptides AB
1 day | +0.17% | ||
1 week | -17.09% | ||
Current month | -54.46% | ||
1 month | -54.46% | ||
3 months | -56.44% | ||
6 months | -57.57% | ||
Current year | -61.36% |
Managers | Title | Age | Since |
---|---|---|---|
Sofia Heigis
CEO | Chief Executive Officer | 44 | 20-07-31 |
Director of Finance/CFO | 50 | Nov. 12 | |
Eva Nordström
COO | Chief Operating Officer | 54 | 11-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Per Wold-Olsen
CHM | Chairman | 76 | 18-05-16 |
Director/Board Member | 63 | 11-12-31 | |
Director/Board Member | 61 | 17-01-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 2.96 | +0.17% | 2,321,014 |
24-04-26 | 2.955 | +2.25% | 1,303,488 |
24-04-25 | 2.89 | -10.25% | 2,636,199 |
24-04-24 | 3.22 | +2.06% | 2,526,246 |
24-04-23 | 3.155 | -11.62% | 1,053,101 |
Delayed Quote Nasdaq Stockholm, April 29, 2024 at 11:29 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-61.36% | 26.75M | |
-2.63% | 102B | |
+1.62% | 96.29B | |
+1.46% | 22.18B | |
-16.67% | 21.2B | |
-8.58% | 18.31B | |
-38.74% | 17.38B | |
-13.21% | 16.36B | |
+5.41% | 13.97B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- ONCO Stock